Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jun 26;109(14):1098-1105.
doi: 10.1136/heartjnl-2022-321760.

Pulmonary artery compliance in different forms of pulmonary hypertension

Affiliations
Observational Study

Pulmonary artery compliance in different forms of pulmonary hypertension

Amber McCormick et al. Heart. .

Abstract

Objective: Pulmonary artery compliance (PAC), estimated as stroke volume (SV) divided by pulmonary artery pulse pressure (PP), may be a predictor of survival in pulmonary arterial hypertension (PAH). Resistance-compliance (RC) time, the product of PAC and pulmonary vascular resistance, is reported to be a physiological constant. We investigated if differences in PAC and RC time exist between pulmonary hypertension (PH) subgroups and examined whether PAC is an independent predictor of transplant-free survival in PAH.

Methods: This was a retrospective analysis of adult PAH (n=532) and chronic thromboembolic PH (CTEPH, n=84) patients enrolled in the US Pulmonary Hypertension Association Registry from 2015 to 2019. PAC and RC time were compared between PH subgroups (connective tissue disease-PAH (CTD-PAH), idiopathic/heritable-PAH (i/h-PAH), drug/toxin-PAH (d/t-PAH)). Cox proportional hazards models were constructed for transplant-free survival, adjusting for REVEAL 2.0 risk score.

Results: There were no differences in estimated PAC between PAH subgroups, nor between PAH and CTEPH. RC time was shorter in CTEPH compared with PAH (median 0.55 (IQR 0.45-0.64) vs 0.62 (0.52-0.73) s, p<0.0001). RC time was shortest in CTD-PAH when compared with i/h-PAH and d/t-PAH ((0.59±0.18) vs (0.65±0.20) vs (0.73±0.25) s, p=0.0001). PAC was associated with transplant-free survival (HR 0.72, 95% CI 0.55 to 0.94, p=0.02) but was not an independent predictor of outcome after adjustment for REVEAL 2.0 score.

Conclusion: PAC was similar between PH groups and was not an independent predictor of transplant-free survival in PAH. RC time was different between PH subgroups, challenging RC time constancy.

Trial registration number: NCT04071327.

Keywords: Pulmonary Arterial Hypertension; Pulmonary Embolism.

PubMed Disclaimer

Conflict of interest statement

Competing interests: ARH: consultant for Bayer, Janssen, United Therapeutics, GossamerBio and Complexa. Holds stock in Tenax Therapeutics. MAS: research support from Novartis. Haemodyanamic core lab for Aadi. Consulting/scientific advisory board for Janssen, Acceleron, Liquidia, Bial, Impulse Dynamics. OAS: consultant and speaker for United Therapeutics, Johnson and Johnson, and Bayer. JSS: research grants from Janssen, PhaseBio, Reata, Bayer, United Therapeutics and Covance. Consultant for Janssen, Bayer and United Therapeutics. TDM: consultant for Actelion/Johnson and Johnson, United Therapeutic, SCIOS-Bial and TrioHealth. Advisory Boards for Altevant and Liquidia; MRL: dlinical trial participation with Gilead, Actelion/Janssen, Bayer, United Therapeutics, Altavant and Acceleron (all funds to the institution).

Comment in

Publication types

Associated data